OncoKB New Data Release - July 2, 2024
Contact OncoKB
Data Release v4.18
July 2, 2024
What's New
Updated HUGO symbol for gene SLC9A3R1 to NHERF1
Updated Therapeutic Implications:
Promotion of tumor type-specific level of evidence for an alteration
Level 1: KRAS G12C in colorectal cancer promoted from Level 2 to Level 1 based on FDA approval of adagrasib + cetuximab for patients with KRAS G12C-mutated colorectal cancer (PMID: 38587856)
Sensitivity-associated evidence currently in OncoKB™ for KRAS G12C (Level 2 in colorectal cancer; Adagrasib + Panitumumab, Sotorasib + Cetuximab, Sotorasib + Panitumumab)
Resistance-associated evidence currently in OncoKB™ for KRAS G12C (Level R1 in colorectal cancer; Tucatinib + Trastuzumab, Cetuximab, Panitumumab)
Level 2: KRAS G12C in biliary tract cancer promoted from Level 3A to Level 2 based on inclusion of adagrasib in the NCCN Biliary Tract Cancer Guidelines V2.2024 (PMID: 37099736)
Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
Level 1: Osimertinib + Chemotherapy added as a combination treatment for EGFR L858R and Exon 19 In-Frame Deletions in non-small cell lung cancer based on FDA approval of osimertinib + chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (PMID: 37937763)
Sensitivity-associated evidence currently in OncoKB™ for EGFR L858R and Exon 19 In-Frame Deletions (Level 1 in non-small cell lung cancer; Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab and Osimertinib)
Level 2: Amivantamab + Chemotherapy added as a combination treatment for EGFR L858R and Exon 19 In-Frame Deletions in non-small cell lung cancer based on inclusion of amivantamab + chemotherapy in the NCCN Non-Small Cell Lung Cancer Guidelines V5.2024 (PMID: 37879444)
Sensitivity-associated evidence currently in OncoKB™ for EGFR L858R and Exon 19 In-Frame Deletions (Level 1 in non-small cell lung cancer; Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab and Osimertinib)
Level 2: Amivantamab + Chemotherapy, Erlotinib, Gefitinib and Dacomitinib added as treatments for EGFR S768I, L861Q and G719X in non-small cell lung cancer based on inclusion of listed treatments in the NCCN Non-Small Cell Lung Cancer Guidelines V5.2024 (PMID: 37879444, 25668120, 35770100)
Sensitivity-associated evidence currently in OncoKB™ for EGFR S768I, L861Q and G719X (Level 1 in non-small cell lung cancer; Afatinib)
Level 2: Tucatinib + Trastuzumab added as a combination treatment for ERBB2 Amplification in biliary tract cancer based on inclusion of tucatinib + trastuzumab in the NCCN Biliary Tract Cancer Guidelines V2.2024 (PMID: 37751561)
Sensitivity-associated evidence currently in OncoKB™ for ERBB2 Amplification (Level 2 in biliary tract cancer; Trastuzumab + Pertuzumab)
Level 3A: Amivantamab + Lazertinib added as a combination treatment for EGFR Exon 19 In-Frame Deletion, L858R, S768I, L861Q and G719X in non-small cell lung cancer based on clinical trial data amivantamab + lazertinib in patients with BRAF-mutated non-small cell lung cancer (PMID: 37710001, 38924756; Abstract: Cho, B.C. et al., Abstract #8516, ASCO 2024)
Sensitivity-associated evidence currently in OncoKB™ for EGFR L858R and Exon 19 In-Frame Deletions (Level 1 in non-small cell lung cancer; Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab and Osimertinib) and EGFR S768I, L861Q and G719X (Level 1 in non-small cell lung cancer; Afatinib)
Changed drug-specific tumor-type level of evidence for an alteration-tumor type-drug association currently in OncoKB (without changing the alteration's highest level of evidence)
Level 1: Repotrectinib promoted from Level 3A to Level 1 for NTRK1, NTRK2 and NTRK3 Fusions in all solid tumors based on FDA approval of repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors (Abstract: Solomon, B.J. et al., Abstract #1372P, Ann Oncol Vol 34, Suppl 2, 2023)
Sensitivity-associated evidence currently in OncoKB™ for NTRK1, NTRK2 and NTRK3 Fusions (Level 1 in all solid tumors; Larotrectinib, Entrectinib)
Gene Curation:
Addition of 4 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
